<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A clinical trial was conducted to assess the feasibility, safety, and efficacy of the <z:hpo ids='HP_0001631'>atrial septal defect</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASD</z:e>) occlusion system for transcatheter closure of <z:mp ids='MP_0010405'>secundum ASD</z:mp> and <z:hpo ids='HP_0001655'>patent foramen ovale</z:hpo> (<z:mp ids='MP_0004225'>PFO</z:mp>) after episodes of <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Occlusion was attempted in 200 patients aged 1 to 74 years (mean 32) </plain></SENT>
<SENT sid="2" pm="."><plain>The procedure failed in 26 patients (13%); the device was retrieved through a catheter in 20 and through surgery in 6 patients </plain></SENT>
<SENT sid="3" pm="."><plain>Procedure-related complications necessitating surgical removal of the device included device embolization in 2, device entrapment within the Chiari network in 1, frame fracture in 1, and <z:mpath ids='MPATH_81'>perforation</z:mpath> of atrial wall in 2 </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 6 patients experienced an uneventful postoperative course </plain></SENT>
<SENT sid="5" pm="."><plain>An additional 11 patients (6%) underwent surgical removal of the device during follow-up </plain></SENT>
<SENT sid="6" pm="."><plain>There were 163 patients (81%) with an implanted <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASD</z:e> occlusion system at follow-up of from 6 to 36 months (mean 17) </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">Thrombus</z:e> formation around the device was detected by transesophageal echocardiography in 9 patients 1 to 4 weeks after implantation </plain></SENT>
<SENT sid="8" pm="."><plain>One of these patients (who had a coagulation <z:hpo ids='HP_0004841'>factor XII deficiency</z:hpo>) suffered a cerebral <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Late atrial wall <z:mpath ids='MPATH_81'>perforation</z:mpath> (5, 6, and 8 months after implantation) occurred in 3 adult patients </plain></SENT>
<SENT sid="10" pm="."><plain>Infectious <z:hpo ids='HP_0100584'>endocarditis</z:hpo> developed in 2 adult patients (1%) </plain></SENT>
<SENT sid="11" pm="."><plain>No late device embolization and no atrioventricular valve injury occurred </plain></SENT>
<SENT sid="12" pm="."><plain>An asymptomatic device frame fracture was found in 14% and frame deformity in 4% of <z:hpo ids='HP_0000001'>all</z:hpo> patients during the follow-up period of &gt;230 patient-years </plain></SENT>
<SENT sid="13" pm="."><plain>Immediately after closure, a moderate/large residual shunt remained in 8% and a small shunt in 29% of patients </plain></SENT>
<SENT sid="14" pm="."><plain>After 1 year, a moderate/large shunt was present in 2% and a small one in 26% of patients </plain></SENT>
<SENT sid="15" pm="."><plain>During a total follow-up of 49 patient-years, only 1 of 46 patients with <z:mp ids='MP_0004225'>PFO</z:mp> had a transient neurologic event after the closure </plain></SENT>
<SENT sid="16" pm="."><plain>The study indicates that patients with centrally situated <z:mp ids='MP_0010405'>secundum ASD</z:mp> and those with <z:mp ids='MP_0004225'>PFO</z:mp> after <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> can be treated with this system with a high success rate and an acceptable morbidity </plain></SENT>
</text></document>